Clinical Trials

    An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)

    Investigator: Sai ravi kiran Pingali

    Study Coordinator:

    Status: Open Not Enrolling

    ClinicalTrials.gov Number: NCT04947319

    Phone:

    Protocol Number: PRO00036153

    Description


    NCT049747319 Brief Summary: This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)